MicroRNAs and atrial fibrillation: Mechanisms and translational potential

Nature Reviews Cardiology

Volumn 12, Issue 2, 2015, Pages 80-90

  Luo, Xiaobin ^a   Yang, Baofeng ^b   Nattel, Stanley ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 133; MICRORNA 208A; MICRORNA 21; MICRORNA 26; MICRORNA 29; MICRORNA 30; MICRORNA 328; MICRORNA 499; MICRORNA 590; NEUROHORMONE; UNCLASSIFIED DRUG; CALCIUM;

GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART MUSCLE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; RNA SYNTHESIS; ATRIAL FIBRILLATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PROCEDURES;

ATRIAL FIBRILLATION; CALCIUM; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC THERAPY; HUMANS; MICRORNAS; MYOCARDIUM;

EID: 84923126851     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.178     Document Type: Review

References (91)

1. Ahmad, Y., Lip, G. Y. & Lane, D. A. Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. Can. J. Cardiol. 29 (Suppl. 7), S4-S13 (2013).
2. Andrade, J., Khairy, P., Dobrev, D. & Nattel, S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ. Res. 114, 1453-1468 (2014).
3. Naccarelli, G. V., Varker, H., Lin, J. & Schulman, K. L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol. 104, 1534-1539 (2009).
4. Murphy, N. F. et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart 93, 606-612 (2007).
5. Nattel, S. New ideas about atrial fibrillation 50 years on. Nature 415, 219-226 (2002).
6. Woods, C. E. & Olgin, J. Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. Circ. Res. 114, 1532-1546 (2014).
7. Nattel, S. & Opie, L. H. Controversies in atrial fibrillation. Lancet 367, 262-272 (2006).
8. Dobrev, D., Carlsson, L. & Nattel, S. Novel molecular targets for atrial fibrillation therapy. Nat. Rev. Drug Discov. 11, 275-291 (2012).
9. Iwasaki, Y. K., Nishida, K., Kato, T. & Nattel, S. Atrial fibrillation pathophysiology: Implications for management. Circulation 124, 2264-2274 (2011).
10. Nattel, S., Burstein, B. & Dobrev, D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ. Arrhythm. Electrophysiol. 1, 62-73 (2008).
11. Wakili, R., Voigt, N., Kaab, S., Dobrev, D. & Nattel, S. Recent advances in the molecular pathophysiology of atrial fibrillation. J. Clin. Invest. 121, 2955-2968 (2011).
12. Schotten, U., Verheule, S., Kirchhof, P. & Goette, A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 91, 265-325 (2011).
13. Nattel, S. & Harada, M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J. Am. Coll. Cardiol. 63, 2335-2345 (2014).
14. Wijffels, M. C., Kirchhof, C. J., Dorland, R. & Allessie, M. A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954-1968 (1995).
15. Yue, L. et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ. Res. 81, 512-525 (1997).
16. Gaborit, N. et al. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation 112, 471-481 (2005).
17. Makary, S. et al. Differential protein kinase C isoform regulation and increased constitutive activity of acetylcholine-regulated potassium channels in atrial remodeling. Circ. Res. 109, 1031-1043 (2011).
18. Brundel, B. J. et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 103, 684-690 (2001).
19. Igarashi, T. et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 125, 216-225 (2012).
20. Bikou. O. et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc. Res. 92, 218-225 (2011).
21. Parkash, R. et al. The association of left atrial size and occurrence of atrial fibrillation: a prospective cohort study from the Canadian Registry of Atrial Fibrillation. Am. Heart J. 148, 649-654 (2004).
22. Zou, R., Kneller, J., Leon, L. J. & Nattel, S. Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. Am. J. Physiol. Heart Circ. Physiol. 289, H1002-H1012 (2005).
23. Frustaci, A. et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96, 1180-1184 (1997).
24. Kalman, J. M., Kumar, S. & Sanders, P. Markers of collagen synthesis, atrial fibrosis, and the mechanisms underlying atrial fibrillation. J. Am. Coll. Cardiol. 60, 1807-1808 (2012).
25. Sinno, H. et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107, 1930-1936 (2003).
26. Anne, W. et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc. Res. 67, 655-666 (2005).
27. Burstein, B., Qi, X. Y., Yeh, Y. H., Calderone, A. & Nattel, S. Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc. Res. 76, 442-452 (2007).
28. Burstein, B., Libby, E., Calderone, A. & Nattel, S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 117, 1630-1641 (2008).
29. Rahmutula, D. et al. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1. Cardiovasc. Res. 99, 769-779 (2013).
30. Chen, P. S., Chen, L. S., Fishbein, M. C., Lin, S. F. & Nattel, S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ. Res. 114, 1500-1515 (2014).
31. Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993).
32. Ambros, V. MicroRNAs: tiny regulators with great potential. Cell 107, 823-826 (2001).
33. Friedman, R. C., Farh, K. K., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92-105 (2009).
34. van Rooij, E. & Olson, E. N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11, 860-872 (2012).
35. Van Rooij, E., Purcell, A. L. & Levin, A. A. Developing microRNA therapeutics. Circ. Res. 110, 496-507 (2012).
36. Denli, A. M., Tops, B. B., Plasterk, R. H., Ketting, R. F. & Hannon, G. J. Processing of primary microRNAs by the Microprocessor complex. Nature 432, 231-235 (2004).
37. Berezikov, E. Evolution of microRNA diversity and regulation in animals. Nat. Rev. Genet. 12, 846-860 (2011).
38. Kim, V. N., Han, J. & Siomi, M. C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10, 126-139 (2009).
39. Gregory, R. I., Chendrimada, T. P., Cooch, N. & Shiekhattar, R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123, 631-640 (2005).
40. Carthew, R. W. & Sontheimer, E. J. Origins and mechanisms of miRNAs and siRNAs. Cell 136, 642-655 (2009).
41. Pillai, R. S., Bhattacharyya, S. N. & Filipowicz, W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 17, 118-126 (2007).
42. Liang, Y., Ridzon, D., Wong, L. & Chen, C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 8, 166 (2007).
43. Luo, X., Zhang, H., Xiao, J. & Wang, Z. Regulation of human cardiac ion channel genes by microRNAs: theoretical perspective and pathophysiological implications. Cell. Physiol. Biochem. 25, 571-586 (2010).
44. Small, E. M., Frost, R. J. & Olson, E. N. MicroRNAs add a new dimension to cardiovascular disease. Circulation 121, 1022-1032 (2010).
45. Lu, Y. et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 122, 2378-2387 (2010).
46. Xiao, J. et al. MicroRNA expression signature in atrial fibrillation with mitral stenosis. Physiol. Genomics 43, 655-664 (2011).
47. Cooley, N. et al. Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiol. Genomics 44, 211-219 (2012).
48. Nishi, H. et al. Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery. PLoS ONE 8, e73397 (2013).
49. Liu, H. et al. Atrial fibrillation alters the microRNA expression profiles of the left atria of patients with mitral stenosis. BMC Cardiovasc. Disord. 14, 10 (2014).
50. Gilad, S. et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 3, e3148 (2008).
51. Liu, Z. et al. The expression levels of plasma microRNAs in atrial fibrillation patients. PLoS ONE 7, e44906 (2012).
52. Goren, Y. et al. Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. Am. J. Cardiol. 113, 976-981 (2014).
53. Dawson, K. et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 127, 1466-1475 (2013).
54. McManus, D. D. et al. Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. Heart Rhythm 11, 663-669 (2014).
55. Yang, B. et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 13, 486-491 (2007).
56. Girmatsion, Z. et al. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm 6, 1802-1809 (2009).
57. Chinchilla, A. et al. PITX2 insufficiency leads to atrial electrical and structural remodeling linked to arrhythmogenesis. Circ. Cardiovasc. Genet. 4, 269-279 (2011).
58. Luo, X. et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J. Clin. Invest. 123, 1939-1951 (2013).
59. Jia, X. et al. MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model. PLoS ONE 8, e85639 (2013).
60. Zicha, S. et al. Molecular basis of species-specific expression of repolarizing K+ currents in the heart. Am. J. Physiol. Heart Circ. Physiol. 285, H1641-H1649 (2003).
61. Harada, M. et al. MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. Circ. Res. 114, 689-705 (2014).
62. Pandit, S. V. et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys. J. 88, 3806-3821 (2005).
63. Callis, T. E. et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119, 2772-2786 (2009).
64. Ling, T. Y. et al. Regulation of the SK3 channel by microRNA-499-potential role in atrial fibrillation. Heart Rhythm 10, 1001-1009 (2013).
65. Ellinor, P. T. et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat. Genet. 42, 240-244 (2010).
66. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984 (2008).
67. Patrick, D. M. et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 120, 3912-3916 (2010).
68. Cardin, S. et al. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ. Arrhythm. Electrophysiol. 5, 1027-1035 (2012).
69. Adam, O. et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res. Cardiol. 107, 278 (2012).
70. Harada, M. et al. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation 126, 2051-2064 (2012).
71. van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105, 13027-13032 (2008).
72. Duisters, R. F. et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104, 170-178 (2009).
73. Li, H., Li, S., Yu, B. & Liu, S. Expression of miR-133 and miR-30 in chronic atrial fibrillation in canines. Mol. Med. Rep. 5, 1457-1460 (2012).
74. Shan, H. et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc. Res. 83, 465-472 (2009).
75. Wahlquist, C. et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508, 531-535 (2014).
76. Karakikes, I. et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J. Am. Heart Assoc. 2, e000078 (2013).
77. Weiler, J., Hunziker, J. & Hall, J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther. 13, 496-502 (2006).
78. Lennox, K. A. & Behlke, M. A. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 18, 1111-1120 (2011).
79. Carè, A. et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13, 613-618 (2007).
80. Montgomery, R. L. et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124, 1537-1547 (2011).
81. Hullinger, T. G. et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 110, 71-81 (2012).
82. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
83. Elmen, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008).
84. Szabo, G. & Bala, S. MicroRNAs in liver disease. Nat. Rev. Gastroenterol. Hepatol. 10, 542-552 (2013).
85. Sayed, D. et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell 19, 3272-3282 (2008).
86. Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721-726 (2007).
87. Choi, W. Y., Giraldez, A. J. & Schier, A. F. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 318, 271-274 (2007).
88. Wang, Z. The principles of MiRNA-masking antisense oligonucleotides technology. Methods Mol. Biol. 676, 43-49 (2011).
89. Hata, A. Functions of microRNAs in cardiovascular biology and disease. Annu. Rev. Physiol. 75, 69-93 (2013).
90. Rao, P. K. et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ. Res. 105, 585-594 (2009).
91. Hu, Y. et al. Epitranscriptional orchestration of genetic reprogramming is an emergent property of stress-regulated cardiac microRNAs. Proc. Natl Acad. Sci. USA 109, 19864-19869 (2012).